Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR6 | P50406 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330423 | 0.90 | SMN1; SMN2 (0.64) | SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2D6 | |
| SCHEMBL2186198 | 0.84 | SMN1; SMN2 (0.58) | SMN1; SMN2ALDH1A1MAPTGAAMEN1 | |
| SCHEMBL2188683 | 0.81 | MAPT (0.53) | SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2D6 | |
| SCHEMBL4425292 | 0.79 | KDM1A (0.47) | SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL1802030 | 0.76 | SMN1; SMN2 (0.65) | SMN1; SMN2ALDH1A1MAPTGAAMEN1 | |
| SCHEMBL2303869 | 0.75 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2D6 | |
| SCHEMBL9094599 | 0.75 | CHRNA7 (0.52) | SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL11706469 | 0.74 | RORC (0.51) | SMN1; SMN2ALDH1A1MAPTCYP1A2CYP2C19 | |
| SCHEMBL2358704 | 0.74 | MPL (0.54) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL30257362 | 0.74 | MPL (0.54) | SMN1; SMN2ALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463502-B1 | BROADSPECTRUM HETEROCYCLIC SUBSTITUTED PHENYL CONTAINING SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARM LTD (IE) | 2011-07-13 | — | — | EP | disclosed |
| US-7763641-B2 | Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2010-07-27 | — | — | US | disclosed |
| CN-100448444-C | Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors | TIBOTEC PHARM LTD (IE) | 2009-01-07 | — | — | CN | disclosed |
| US-20050222215-A1 | Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2005-10-06 | — | — | US | disclosed |
| CN-1620292-A | Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors | TIBOTEC PHARM LTD (IE) | 2005-05-25 | — | — | CN | disclosed |
| EP-1463502-A1 | BROADSPECTRUM HETEROCYCLIC SUBSTITUTED PHENYL CONTAINING SULFONAMIDE HIV PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003053435-A1 | BROADSPECTRUM HETEROCYCLIC SUBSTITUTED PHENYL CONTAINING SULFONAMIDE HIV PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD (IE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222215-A1 | Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors | CYP2S1, PRSS1, AHCYL1 | SMN1; SMN2 3870/4885ALDH1A1 1473/4885MAPT 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.